---
title: "翰森製藥：B7-H3 靶向抗體藥物偶聯物 HS-20093 用於後線復發或難治性骨肉瘤獲 FDA 突破性療法認定"
description: "翰森製藥宣佈，其 B7-H3 靶向抗體藥物偶聯物 HS-20093 獲得美國 FDA 的突破性療法認定，適用於後線復發或難治性骨肉瘤患者。該藥物由全人源抗 B7-H3 單抗與拓撲異構酶抑制劑有效載荷共價連接而成，目前在中國進行多項臨牀研究，涵蓋肺癌、肉瘤、頭頸癌等多種實體瘤。"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/224183949.md"
published_at: "2025-01-07T11:20:03.000Z"
---

# 翰森製藥：B7-H3 靶向抗體藥物偶聯物 HS-20093 用於後線復發或難治性骨肉瘤獲 FDA 突破性療法認定

> 翰森製藥宣佈，其 B7-H3 靶向抗體藥物偶聯物 HS-20093 獲得美國 FDA 的突破性療法認定，適用於後線復發或難治性骨肉瘤患者。該藥物由全人源抗 B7-H3 單抗與拓撲異構酶抑制劑有效載荷共價連接而成，目前在中國進行多項臨牀研究，涵蓋肺癌、肉瘤、頭頸癌等多種實體瘤。

智通財經 APP 訊，翰森製藥 (03692) 公佈，GSK 就 GSK5764227(GSK’227，亦稱 HS-20093) 獲美國食品藥品監督管理局 (FDA) 授予突破性療法認定 (BTD)，此 B7-H3 靶向抗體藥物偶聯物 (ADC) 正在評估用於治療既往經二線及以上治療進展的復發或難治性骨肉瘤 (骨癌) 成人患者。

HS-20093 是一種新型 B7-H3 靶向 ADC，由全人源抗 B7-H3 單抗與拓撲異構酶抑制劑 (TOPOi) 有效載荷共價連接而成，正於中國開展用於治療肺癌、肉瘤、頭頸癌以及其他實體瘤的多項 I 期、II 期及 III 期臨牀研究。

### Related Stocks

- [03692.HK - 翰森制藥](https://longbridge.com/zh-HK/quote/03692.HK.md)
- [300942.CN - 易瑞生物](https://longbridge.com/zh-HK/quote/300942.CN.md)
- [GSK.US - 葛蘭素史克](https://longbridge.com/zh-HK/quote/GSK.US.md)
- [600521.CN - 華海藥業](https://longbridge.com/zh-HK/quote/600521.CN.md)
- [301234.CN - 五洲醫療](https://longbridge.com/zh-HK/quote/301234.CN.md)
- [688553.CN - 匯宇制藥-W](https://longbridge.com/zh-HK/quote/688553.CN.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Hansoh Pharmaceutical Says Aumolertinib Mesylate Tablets Approved In EU As Monotherapy | Hansoh Pharmaceutical Group Company Ltd :AUMOLERTINIB MESYLATE TABLETS APPROVED IN EU AS MONOTHERAPY | [Link](https://longbridge.com/zh-HK/news/276401882.md) |
| Hansoh Pharmaceutical Group Company Limited Announces Approval in the European Union as Monotherapy | Hansoh Pharmaceutical Group Company Limited announced that Aumolertinib Mesylate Tablets, known as Ameile in China, rece | [Link](https://longbridge.com/zh-HK/news/276480305.md) |
| Hansoh Wins EU Approval for Key Lung Cancer Drug Aumolertinib | Hansoh Wins EU Approval for Key Lung Cancer Drug Aumolertinib | [Link](https://longbridge.com/zh-HK/news/276393466.md) |
| Nomura Adjusts Hansoh Pharmaceutical Group's Price Target to HK$37.87 From HK$35.50, Keeps at Neutral | Nomura Adjusts Hansoh Pharmaceutical Group's Price Target to HK$37.87 From HK$35.50, Keeps at Neutral | [Link](https://longbridge.com/zh-HK/news/276056784.md) |
| Bessent Says Possible 2026 Tariff Revenue Largely Unchanged | Bessent Says Possible 2026 Tariff Revenue Largely Unchanged | [Link](https://longbridge.com/zh-HK/news/276480273.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。
